

Attorney Docket No. PB60162A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andreotti et al. November 28, 2007
Serial No.: 10/522,493 Group Art Unit No.: 1625
Filed: September 21, 2006
For: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF
RECEPTOR ANTAGONISTS

FILING OF AN INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Laura K. Madden
Attorney for Applicants
Registration No. 48,352

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7339
Facsimile (610) 270-5090